BMEA BIOMEA FUSION INC

Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference

Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference

SAN CARLOS, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that Mick Hitchcock, Ph.D., Interim Chief Executive Officer and Board Member, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 from 5:15 PM to 5:55 PM Pacific Time. Additionally, Biomea’s management team will host one-on-one meetings throughout the conference, which will take place from January 12-15.

A live audio webcast of the presentation can be accessed or by visiting the Investors & Media section of Biomea’s website at . A replay of the webcast will be available following the live presentation.

About Biomea Fusion

Biomea Fusion is a clinical-stage biopharmaceutical company advancing oral small molecule therapies, icovamenib and BMF-650, for diabetes and obesity. These programs target metabolic disorders, a global health challenge affecting nearly half of Americans and one-fifth of the world’s population. Biomea’s mission is to deliver transformative treatments that restore health for patients living with diabetes, obesity, and related conditions. We aim to cure.

Visit us at biomeafusion.com and follow us on , and .

Contact:

Meichiel Jennifer Weiss

Sr. Director of Investor Relations and Corporate Development



EN
17/12/2025

Underlying

BMEABIOMEA FUSION INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BIOMEA FUSION INC

 PRESS RELEASE
Free
BMEA BIOMEA FUSION I...

Biomea Fusion Reports Full Year 2025 Financial Results and Corporate H...

Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights Initiated two Phase II trials COVALENT-211 and COVALENT-212 (icovamenib in type 2 diabetes) with 26-week primary endpoint data anticipated in the fourth quarter of 2026Completed 52-week follow-up from Phase II trial COVALENT-112 (icovamenib in type 1 diabetes) with data expected in the second quarter of 2026Initiated Phase I trial enrollment of GLP-131 (BMF-650 in obesity) with initial 28-day weight reduction data expected in the second quarter of 2026Projected cash runway into the first quarter of 2027 SAN CAR...

March 24, 2026 1 EN
 PRESS RELEASE
Free
BMEA BIOMEA FUSION I...

Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes a...

Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026 SAN CARLOS, Calif., March 14, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion,” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that Juan Pablo Frías, MD, delivered an oral presentation at the 19th International Conference on Advanced Technologies & Treatments for Diabetes (“ATTD”) in Barcelona on March 14, 2026 highlighting positive 52-week follow-up results...

March 14, 2026 1 EN
 PRESS RELEASE
Free
BMEA BIOMEA FUSION I...

Biomea Fusion to Participate at Upcoming Investor Conferences

Biomea Fusion to Participate at Upcoming Investor Conferences SAN CARLOS, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Company” or “Company management”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that it will participate in the following upcoming investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences Conference: Biomea will present virtually on February 26, 2026, at 10:00 AM (EDT). Company management will also meet with investors in one-on-one meetings during the conference.The Citizens Life Sciences Confe...

February 19, 2026 1 EN
 PRESS RELEASE
Free
BMEA BIOMEA FUSION I...

Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-...

Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 Milestones Advancing icovamenib toward late-stage clinical development in two Phase II clinical trials in patients with insulin-deficient type 2 diabetes (“T2D”) and in T2D patients currently failing glucagon-like peptide-1 (“GLP-1”) based therapiesSuccessfully completed icovamenib food-effect study, establishing optimal dosing conditions to support late-stage clinical studies Successfully completed icovamenib chronic toxicology studies, supporting potential flexibility to evaluate clinical dosing beyond the validated...

January 12, 2026 1 EN
 PRESS RELEASE
Free
BMEA BIOMEA FUSION I...

Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Con...

Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference SAN CARLOS, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that Mick Hitchcock, Ph.D., Interim Chief Executive Officer and Board Member, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 from 5:15 PM to 5:55 PM Pacific Time. Additionally, Biomea’s management team will host one-on-one meetings throughout the conference, which will take place from January 12-15. A...

December 17, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch